메뉴 건너뛰기




Volumn 39, Issue 1, 2013, Pages 101-111

Thrombotic and bleeding complications in classical myeloproliferative neoplasms

Author keywords

essential thrombocythemia; hemorrhage; myelofibrosis; myeloproliferative neoplasm; polycythemia vera; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANAGRELIDE; ANTICOAGULANT AGENT; BETA THROMBOGLOBULIN; BUSULFAN; CLOPIDOGREL; HYDROXYUREA; INTERFERON; JANUS KINASE 2; JANUS KINASE INHIBITOR; PADGEM PROTEIN; PIPOBROMAN; THROMBIN;

EID: 84873412020     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1331153     Document Type: Article
Times cited : (40)

References (101)
  • 1
    • 79954571305 scopus 로고    scopus 로고
    • Myeloid blastic transformation of myeloproliferative neoplasms-a review of 112 cases
    • Noor S. J., Tan W., Wilding G. E., et al. Myeloid blastic transformation of myeloproliferative neoplasms-a review of 112 cases. Leuk Res: 2011; 35 5 608 613
    • (2011) Leuk Res , vol.35 , Issue.5 , pp. 608-613
    • Noor, S.J.1    Tan, W.2    Wilding, G.E.3
  • 2
    • 0031046884 scopus 로고    scopus 로고
    • The very long-term evolution of polycythemia vera: An analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981
    • Najean Y., Rain J. D. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol: 1997; 34 1 6 16
    • (1997) Semin Hematol , vol.34 , Issue.1 , pp. 6-16
    • Najean, Y.1    Rain, J.D.2
  • 3
    • 80051803115 scopus 로고    scopus 로고
    • Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study
    • Barbui T., Thiele J., Passamonti F., et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol: 2011; 29 23 3179 3184
    • (2011) J Clin Oncol , vol.29 , Issue.23 , pp. 3179-3184
    • Barbui, T.1    Thiele, J.2    Passamonti, F.3
  • 4
    • 84856946984 scopus 로고    scopus 로고
    • Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management
    • Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol: 2012; 87 3 285 293
    • (2012) Am J Hematol , vol.87 , Issue.3 , pp. 285-293
    • Tefferi, A.1
  • 5
    • 77953068974 scopus 로고    scopus 로고
    • A retrospective study on 226 polycythemia vera patients: Impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs
    • Crisà E., Venturino E., Passera R., et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol: 2010; 89 7 691 699
    • (2010) Ann Hematol , vol.89 , Issue.7 , pp. 691-699
    • Crisà, E.1    Venturino, E.2    Passera, R.3
  • 6
    • 43549125836 scopus 로고    scopus 로고
    • A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
    • Passamonti F., Rumi E., Caramella M., et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood: 2008; 111 7 3383 3387
    • (2008) Blood , vol.111 , Issue.7 , pp. 3383-3387
    • Passamonti, F.1    Rumi, E.2    Caramella, M.3
  • 7
    • 77949328094 scopus 로고    scopus 로고
    • Thrombosis in primary myelofibrosis: Incidence and risk factors
    • Barbui T., Carobbio A., Cervantes F., et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood: 2010; 115 4 778 782
    • (2010) Blood , vol.115 , Issue.4 , pp. 778-782
    • Barbui, T.1    Carobbio, A.2    Cervantes, F.3
  • 8
    • 34249949626 scopus 로고    scopus 로고
    • Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F
    • Tefferi A., Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost: 2007; 33 4 313 320
    • (2007) Semin Thromb Hemost , vol.33 , Issue.4 , pp. 313-320
    • Tefferi, A.1    Elliott, M.2
  • 10
    • 84859631134 scopus 로고    scopus 로고
    • Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera
    • Reikvam H., Tiu R. V. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia: 2012; 26 4 563 571
    • (2012) Leukemia , vol.26 , Issue.4 , pp. 563-571
    • Reikvam, H.1    Tiu, R.V.2
  • 11
    • 68249099452 scopus 로고    scopus 로고
    • Etiology, management, and outcome of the Budd-Chiari syndrome
    • EN-Vie (European Network for Vascular Disorders of the Liver)
    • Darwish Murad S., Plessier A., Hernandez-Guerra M., et al. EN-Vie (European Network for Vascular Disorders of the Liver) Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med: 2009; 151 3 167 175
    • (2009) Ann Intern Med , vol.151 , Issue.3 , pp. 167-175
    • Darwish Murad, S.1    Plessier, A.2    Hernandez-Guerra, M.3
  • 12
    • 34147156839 scopus 로고    scopus 로고
    • Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders
    • De Stefano V., Fiorini A., Rossi E., et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost: 2007; 5 4 708 714
    • (2007) J Thromb Haemost , vol.5 , Issue.4 , pp. 708-714
    • De Stefano, V.1    Fiorini, A.2    Rossi, E.3
  • 13
    • 33845546565 scopus 로고    scopus 로고
    • The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis
    • Colaizzo D., Amitrano L., Tiscia G. L., et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost: 2007; 5 1 55 61
    • (2007) J Thromb Haemost , vol.5 , Issue.1 , pp. 55-61
    • Colaizzo, D.1    Amitrano, L.2    Tiscia, G.L.3
  • 14
    • 46749132374 scopus 로고    scopus 로고
    • The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: A report on 241 cases
    • Kiladjian J. J., Cervantes F., Leebeek F. W., et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood: 2008; 111 10 4922 4929
    • (2008) Blood , vol.111 , Issue.10 , pp. 4922-4929
    • Kiladjian, J.J.1    Cervantes, F.2    Leebeek, F.W.3
  • 15
    • 67049173799 scopus 로고    scopus 로고
    • JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: A meta-analysis
    • Dentali F., Squizzato A., Brivio L., et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood: 2009; 113 22 5617 5623
    • (2009) Blood , vol.113 , Issue.22 , pp. 5617-5623
    • Dentali, F.1    Squizzato, A.2    Brivio, L.3
  • 16
    • 77957779176 scopus 로고    scopus 로고
    • Thrombosis in myelofibrosis: Prior thrombosis is the only predictive factor and most venous events are provoked
    • Elliott M. A., Pardanani A., Lasho T. L., Schwager S. M., Tefferi A. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica: 2010; 95 10 1788 1791
    • (2010) Haematologica , vol.95 , Issue.10 , pp. 1788-1791
    • Elliott, M.A.1    Pardanani, A.2    Lasho, T.L.3    Schwager, S.M.4    Tefferi, A.5
  • 17
    • 20244389579 scopus 로고    scopus 로고
    • Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
    • Marchioli R., Finazzi G., Landolfi R., et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol: 2005; 23 10 2224 2232
    • (2005) J Clin Oncol , vol.23 , Issue.10 , pp. 2224-2232
    • Marchioli, R.1    Finazzi, G.2    Landolfi, R.3
  • 18
    • 21444434751 scopus 로고    scopus 로고
    • Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
    • United Kingdom Medical Research Council Primary Thrombocythemia 1 Study
    • Harrison C. N., Campbell P. J., Buck G., et al. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med: 2005; 353 1 33 45
    • (2005) N Engl J Med , vol.353 , Issue.1 , pp. 33-45
    • Harrison, C.N.1    Campbell, P.J.2    Buck, G.3
  • 19
    • 40849085151 scopus 로고    scopus 로고
    • Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments
    • GIMEMA CMD-Working Party
    • De Stefano V., Za T., Rossi E., et al. GIMEMA CMD-Working Party Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica: 2008; 93 3 372 380
    • (2008) Haematologica , vol.93 , Issue.3 , pp. 372-380
    • De Stefano, V.1    Za, T.2    Rossi, E.3
  • 20
    • 0029847674 scopus 로고    scopus 로고
    • Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation
    • van Genderen P. J., Lucas I. S., van Strik R., et al. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost: 1996; 76 3 333 338
    • (1996) Thromb Haemost , vol.76 , Issue.3 , pp. 333-338
    • Van Genderen, P.J.1    Lucas, I.S.2    Van Strik, R.3
  • 21
    • 0016738658 scopus 로고
    • Platelet function in patients with high platelet counts
    • Ginsburg A. D. Platelet function in patients with high platelet counts. Ann Intern Med: 1975; 82 4 506 511
    • (1975) Ann Intern Med , vol.82 , Issue.4 , pp. 506-511
    • Ginsburg, A.D.1
  • 22
    • 0033871736 scopus 로고    scopus 로고
    • Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders
    • Jensen M. K., de Nully Brown P., Lund B. V., Nielsen O. J., Hasselbalch H. C. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol: 2000; 110 1 116 124
    • (2000) Br J Haematol , vol.110 , Issue.1 , pp. 116-124
    • Jensen, M.K.1    De Nully Brown, P.2    Lund, B.V.3    Nielsen, O.J.4    Hasselbalch, H.C.5
  • 23
    • 0026808372 scopus 로고
    • Increased thromboxane biosynthesis in patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation in vivo
    • Landolfi R., Ciabattoni G., Patrignani P., et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood: 1992; 80 8 1965 1971
    • (1992) Blood , vol.80 , Issue.8 , pp. 1965-1971
    • Landolfi, R.1    Ciabattoni, G.2    Patrignani, P.3
  • 24
    • 0028809443 scopus 로고
    • Increased thromboxane biosynthesis in essential thrombocythemia
    • Rocca B., Ciabattoni G., Tartaglione R., et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost: 1995; 74 5 1225 1230
    • (1995) Thromb Haemost , vol.74 , Issue.5 , pp. 1225-1230
    • Rocca, B.1    Ciabattoni, G.2    Tartaglione, R.3
  • 25
    • 51649130509 scopus 로고    scopus 로고
    • Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients
    • Santilli F., Romano M., Recchiuti A., et al. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood: 2008; 112 4 1085 1090
    • (2008) Blood , vol.112 , Issue.4 , pp. 1085-1090
    • Santilli, F.1    Romano, M.2    Recchiuti, A.3
  • 26
    • 0018181405 scopus 로고
    • Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia
    • Pearson T. C., Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet: 1978; 2 8102 1219 1222
    • (1978) Lancet , vol.2 , Issue.8102 , pp. 1219-1222
    • Pearson, T.C.1    Wetherley-Mein, G.2
  • 27
    • 17844390356 scopus 로고    scopus 로고
    • Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera
    • Falanga A., Marchetti M., Vignoli A., Balducci D., Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol: 2005; 33 5 523 530
    • (2005) Exp Hematol , vol.33 , Issue.5 , pp. 523-530
    • Falanga, A.1    Marchetti, M.2    Vignoli, A.3    Balducci, D.4    Barbui, T.5
  • 28
    • 67649402606 scopus 로고    scopus 로고
    • Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: Is leukocytosis a causative factor
    • Barbui T., Carobbio A., Rambaldi A., Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood: 2009; 114 4 759 763
    • (2009) Blood , vol.114 , Issue.4 , pp. 759-763
    • Barbui, T.1    Carobbio, A.2    Rambaldi, A.3    Finazzi, G.4
  • 29
    • 34447619693 scopus 로고    scopus 로고
    • Platelet and coagulation activation markers in myeloproliferative diseases: Relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies
    • Robertson B., Urquhart C., Ford I., et al. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies. J Thromb Haemost: 2007; 5 8 1679 1685
    • (2007) J Thromb Haemost , vol.5 , Issue.8 , pp. 1679-1685
    • Robertson, B.1    Urquhart, C.2    Ford, I.3
  • 30
    • 34547952655 scopus 로고    scopus 로고
    • Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM
    • Wautier M. P., El Nemer W., Gane P., et al. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM. Blood: 2007; 110 3 894 901
    • (2007) Blood , vol.110 , Issue.3 , pp. 894-901
    • Wautier, M.P.1    El Nemer, W.2    Gane, P.3
  • 31
    • 48449088506 scopus 로고    scopus 로고
    • Microparticles in vascular diseases
    • 01
    • George F. D. Microparticles in vascular diseases. Thromb Res: 2008; 122 01 S55 S59
    • (2008) Thromb Res , vol.122
    • George, F.D.1
  • 32
    • 67650727986 scopus 로고    scopus 로고
    • Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia
    • Trappenburg M. C., van Schilfgaarde M., Marchetti M., et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica: 2009; 94 7 911 918
    • (2009) Haematologica , vol.94 , Issue.7 , pp. 911-918
    • Trappenburg, M.C.1    Van Schilfgaarde, M.2    Marchetti, M.3
  • 33
    • 78149284944 scopus 로고    scopus 로고
    • Flow cytometry-evaluated platelet CD36 expression, reticulated platelets and platelet microparticles in essential thrombocythaemia and secondary thrombocytosis
    • Moles-Moreau M. P., Ternisien C., Tanguy-Schmidt A., et al. Flow cytometry-evaluated platelet CD36 expression, reticulated platelets and platelet microparticles in essential thrombocythaemia and secondary thrombocytosis. Thromb Res: 2010; 126 5 e394 e396
    • (2010) Thromb Res , vol.126 , Issue.5
    • Moles-Moreau, M.P.1    Ternisien, C.2    Tanguy-Schmidt, A.3
  • 34
    • 77956268837 scopus 로고    scopus 로고
    • Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms
    • Duchemin J., Ugo V., Ianotto J. C., Lecucq L., Mercier B., Abgrall J. F. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res: 2010; 126 3 238 242
    • (2010) Thromb Res , vol.126 , Issue.3 , pp. 238-242
    • Duchemin, J.1    Ugo, V.2    Ianotto, J.C.3    Lecucq, L.4    Mercier, B.5    Abgrall, J.F.6
  • 35
    • 67149133738 scopus 로고    scopus 로고
    • The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome
    • Sozer S., Fiel M. I., Schiano T., Xu M., Mascarenhas J., Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood: 2009; 113 21 5246 5249
    • (2009) Blood , vol.113 , Issue.21 , pp. 5246-5249
    • Sozer, S.1    Fiel, M.I.2    Schiano, T.3    Xu, M.4    Mascarenhas, J.5    Hoffman, R.6
  • 36
    • 79953071111 scopus 로고    scopus 로고
    • Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms
    • Teofili L., Martini M., Iachininoto M. G., et al. Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood: 2011; 117 9 2700 2707
    • (2011) Blood , vol.117 , Issue.9 , pp. 2700-2707
    • Teofili, L.1    Martini, M.2    Iachininoto, M.G.3
  • 37
    • 28244442441 scopus 로고    scopus 로고
    • Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study
    • United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group
    • Campbell P. J., Scott L. M., Buck G., et al. United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet: 2005; 366 9501 1945 1953
    • (2005) Lancet , vol.366 , Issue.9501 , pp. 1945-1953
    • Campbell, P.J.1    Scott, L.M.2    Buck, G.3
  • 38
    • 68549136745 scopus 로고    scopus 로고
    • JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera
    • Carobbio A., Finazzi G., Antonioli E., et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol: 2009; 37 9 1016 1021
    • (2009) Exp Hematol , vol.37 , Issue.9 , pp. 1016-1021
    • Carobbio, A.1    Finazzi, G.2    Antonioli, E.3
  • 39
    • 68549116852 scopus 로고    scopus 로고
    • Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review
    • Lussana F., Caberlon S., Pagani C., Kamphuisen P. W., Büller H. R., Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res: 2009; 124 4 409 417
    • (2009) Thromb Res , vol.124 , Issue.4 , pp. 409-417
    • Lussana, F.1    Caberlon, S.2    Pagani, C.3    Kamphuisen, P.W.4    Büller, H.R.5    Cattaneo, M.6
  • 40
    • 34547953018 scopus 로고    scopus 로고
    • Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia
    • Vannucchi A. M., Antonioli E., Guglielmelli P., et al. Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia. Blood: 2007; 110 3 840 846
    • (2007) Blood , vol.110 , Issue.3 , pp. 840-846
    • Vannucchi, A.M.1    Antonioli, E.2    Guglielmelli, P.3
  • 41
    • 34548136101 scopus 로고    scopus 로고
    • Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden
    • MPD Research Consortium
    • Vannucchi A. M., Antonioli E., Guglielmelli P., et al. MPD Research Consortium Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia: 2007; 21 9 1952 1959
    • (2007) Leukemia , vol.21 , Issue.9 , pp. 1952-1959
    • Vannucchi, A.M.1    Antonioli, E.2    Guglielmelli, P.3
  • 42
    • 38549135526 scopus 로고    scopus 로고
    • Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia
    • Myeloproliferative Disorders Research Consortium (MPD-RC)
    • Antonioli E., Guglielmelli P., Poli G., et al. Myeloproliferative Disorders Research Consortium (MPD-RC) Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica: 2008; 93 1 41 48
    • (2008) Haematologica , vol.93 , Issue.1 , pp. 41-48
    • Antonioli, E.1    Guglielmelli, P.2    Poli, G.3
  • 43
    • 79551607979 scopus 로고    scopus 로고
    • Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
    • Passamonti F., Elena C., Schnittger S., et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood: 2011; 117 10 2813 2816
    • (2011) Blood , vol.117 , Issue.10 , pp. 2813-2816
    • Passamonti, F.1    Elena, C.2    Schnittger, S.3
  • 44
    • 50949127379 scopus 로고    scopus 로고
    • Characteristics and clinical correlates of MPL 515W > L/K mutation in essential thrombocythemia
    • Vannucchi A. M., Antonioli E., Guglielmelli P., et al. Characteristics and clinical correlates of MPL 515W > L/K mutation in essential thrombocythemia. Blood: 2008; 112 3 844 847
    • (2008) Blood , vol.112 , Issue.3 , pp. 844-847
    • Vannucchi, A.M.1    Antonioli, E.2    Guglielmelli, P.3
  • 45
    • 47249092413 scopus 로고    scopus 로고
    • MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort
    • Beer P. A., Campbell P. J., Scott L. M., et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood: 2008; 112 1 141 149
    • (2008) Blood , vol.112 , Issue.1 , pp. 141-149
    • Beer, P.A.1    Campbell, P.J.2    Scott, L.M.3
  • 46
    • 67349124376 scopus 로고    scopus 로고
    • TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
    • Tefferi A., Pardanani A., Lim K. H., et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia: 2009; 23 5 905 911
    • (2009) Leukemia , vol.23 , Issue.5 , pp. 905-911
    • Tefferi, A.1    Pardanani, A.2    Lim, K.H.3
  • 47
    • 84858062280 scopus 로고    scopus 로고
    • Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
    • Barbui T., Thiele J., Passamonti F., et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood: 2012; 119 10 2239 2241
    • (2012) Blood , vol.119 , Issue.10 , pp. 2239-2241
    • Barbui, T.1    Thiele, J.2    Passamonti, F.3
  • 48
    • 79551644817 scopus 로고    scopus 로고
    • Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: Different role of C-reactive protein and pentraxin 3
    • AGIMM and IIC Investigators
    • Barbui T., Carobbio A., Finazzi G., et al. AGIMM and IIC Investigators Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica: 2011; 96 2 315 318
    • (2011) Haematologica , vol.96 , Issue.2 , pp. 315-318
    • Barbui, T.1    Carobbio, A.2    Finazzi, G.3
  • 49
    • 79551491928 scopus 로고    scopus 로고
    • Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet
    • European LeukemiaNet
    • Barbui T., Barosi G., Birgegard G., et al. European LeukemiaNet Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol: 2011; 29 6 761 770
    • (2011) J Clin Oncol , vol.29 , Issue.6 , pp. 761-770
    • Barbui, T.1    Barosi, G.2    Birgegard, G.3
  • 50
    • 79952075257 scopus 로고    scopus 로고
    • Myeloproliferative neoplasms: Molecular pathophysiology, essential clinical understanding, and treatment strategies
    • Tefferi A., Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol: 2011; 29 5 573 582
    • (2011) J Clin Oncol , vol.29 , Issue.5 , pp. 573-582
    • Tefferi, A.1    Vainchenker, W.2
  • 51
    • 0028844554 scopus 로고
    • Polycythemia vera: The natural history of 1213 patients followed for 20 years
    • Gruppo Italiano Studio Policitemia
    • Gruppo Italiano Studio Policitemia Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med: 1995; 123 9 656 664
    • (1995) Ann Intern Med , vol.123 , Issue.9 , pp. 656-664
  • 52
    • 34848858920 scopus 로고    scopus 로고
    • Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia
    • Radaelli F., Colombi M., Calori R., et al. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia. Hematol Oncol: 2007; 25 3 115 120
    • (2007) Hematol Oncol , vol.25 , Issue.3 , pp. 115-120
    • Radaelli, F.1    Colombi, M.2    Calori, R.3
  • 53
    • 0346727336 scopus 로고    scopus 로고
    • Efficacy and safety of low-dose aspirin in polycythemia vera
    • European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators
    • Landolfi R., Marchioli R., Kutti J., et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med: 2004; 350 2 114 124
    • (2004) N Engl J Med , vol.350 , Issue.2 , pp. 114-124
    • Landolfi, R.1    Marchioli, R.2    Kutti, J.3
  • 54
    • 33749351784 scopus 로고    scopus 로고
    • Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; Does number matter
    • Tefferi A., Gangat N., Wolanskyj A. P. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood: 2006; 108 7 2493 2494
    • (2006) Blood , vol.108 , Issue.7 , pp. 2493-2494
    • Tefferi, A.1    Gangat, N.2    Wolanskyj, A.P.3
  • 55
    • 84865229049 scopus 로고    scopus 로고
    • Correlation of blood counts with vascular complications in essential thrombocythemia: Analysis of the prospective PT1 cohort
    • Campbell P. J., MacLean C., Beer P. A., et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood: 2012; 120 7 1409 1411
    • (2012) Blood , vol.120 , Issue.7 , pp. 1409-1411
    • Campbell, P.J.1    MacLean, C.2    Beer, P.A.3
  • 56
    • 32144461605 scopus 로고    scopus 로고
    • Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors
    • Wolanskyj A. P., Schwager S. M., McClure R. F., Larson D. R., Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc: 2006; 81 2 159 166
    • (2006) Mayo Clin Proc , vol.81 , Issue.2 , pp. 159-166
    • Wolanskyj, A.P.1    Schwager, S.M.2    McClure, R.F.3    Larson, D.R.4    Tefferi, A.5
  • 57
    • 33947208087 scopus 로고    scopus 로고
    • Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
    • European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP)
    • Landolfi R., Di Gennaro L., Barbui T., et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood: 2007; 109 6 2446 2452
    • (2007) Blood , vol.109 , Issue.6 , pp. 2446-2452
    • Landolfi, R.1    Di Gennaro, L.2    Barbui, T.3
  • 58
    • 75449098063 scopus 로고    scopus 로고
    • Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia
    • GIMEMA Chronic Myeloproliferative Neoplasms Working Party
    • De Stefano V., Za T., Rossi E., et al. GIMEMA Chronic Myeloproliferative Neoplasms Working Party Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol: 2010; 85 2 97 100
    • (2010) Am J Hematol , vol.85 , Issue.2 , pp. 97-100
    • De Stefano, V.1    Za, T.2    Rossi, E.3
  • 59
    • 84862518266 scopus 로고    scopus 로고
    • Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients
    • Buxhofer-Ausch V., Gisslinger H., Thiele J., et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol: 2012; 87 7 669 672
    • (2012) Am J Hematol , vol.87 , Issue.7 , pp. 669-672
    • Buxhofer-Ausch, V.1    Gisslinger, H.2    Thiele, J.3
  • 60
    • 0034672149 scopus 로고    scopus 로고
    • Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera
    • Falanga A., Marchetti M., Evangelista V., et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood: 2000; 96 13 4261 4266
    • (2000) Blood , vol.96 , Issue.13 , pp. 4261-4266
    • Falanga, A.1    Marchetti, M.2    Evangelista, V.3
  • 61
    • 73149090129 scopus 로고    scopus 로고
    • Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera
    • Gangat N., Wolanskyj A. P., Schwager S. M., Hanson C. A., Tefferi A. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer: 2009; 115 24 5740 5745
    • (2009) Cancer , vol.115 , Issue.24 , pp. 5740-5745
    • Gangat, N.1    Wolanskyj, A.P.2    Schwager, S.M.3    Hanson, C.A.4    Tefferi, A.5
  • 62
    • 78149470436 scopus 로고    scopus 로고
    • Thrombohemorrhagic complications of myeloproliferative disorders
    • Papadakis E., Hoffman R., Brenner B. Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev: 2010; 24 6 227 232
    • (2010) Blood Rev , vol.24 , Issue.6 , pp. 227-232
    • Papadakis, E.1    Hoffman, R.2    Brenner, B.3
  • 63
    • 0036735354 scopus 로고    scopus 로고
    • Factor v Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia
    • Ruggeri M., Gisslinger H., Tosetto A., et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol: 2002; 71 1 1 6
    • (2002) Am J Hematol , vol.71 , Issue.1 , pp. 1-6
    • Ruggeri, M.1    Gisslinger, H.2    Tosetto, A.3
  • 64
    • 15244363669 scopus 로고    scopus 로고
    • Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: A cohort study
    • Gisslinger H., Müllner M., Pabinger I., et al. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study. Haematologica: 2005; 90 3 408 410
    • (2005) Haematologica , vol.90 , Issue.3 , pp. 408-410
    • Gisslinger, H.1    Müllner, M.2    Pabinger, I.3
  • 65
    • 0022743990 scopus 로고
    • Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera
    • Tartaglia A. P., Goldberg J. D., Berk P. D., Wasserman L. R. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol: 1986; 23 3 172 176
    • (1986) Semin Hematol , vol.23 , Issue.3 , pp. 172-176
    • Tartaglia, A.P.1    Goldberg, J.D.2    Berk, P.D.3    Wasserman, L.R.4
  • 66
    • 84983134916 scopus 로고    scopus 로고
    • Low-dose aspirin in polycythaemia vera: A pilot study
    • Gruppo Italiano Studio Policitemia (GISP)
    • Gruppo Italiano Studio Policitemia (GISP) Low-dose aspirin in polycythaemia vera: a pilot study. Br J Haematol: 1997; 97 2 453 456
    • (1997) Br J Haematol , vol.97 , Issue.2 , pp. 453-456
  • 67
    • 77956524019 scopus 로고    scopus 로고
    • Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
    • quiz 1387
    • Alvarez-Larrán A., Cervantes F., Pereira A., et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood: 2010; 116 8 1205 1210, quiz 1387
    • (2010) Blood , vol.116 , Issue.8 , pp. 1205-1210
    • Alvarez-Larrán, A.1    Cervantes, F.2    Pereira, A.3
  • 68
    • 84856946984 scopus 로고    scopus 로고
    • Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management
    • Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol: 2012; 87 3 285 293
    • (2012) Am J Hematol , vol.87 , Issue.3 , pp. 285-293
    • Tefferi, A.1
  • 69
    • 44949094483 scopus 로고    scopus 로고
    • Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia
    • Squizzato A., Romualdi E., Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev: 2008; 2 CD006503
    • (2008) Cochrane Database Syst Rev , Issue.2
    • Squizzato, A.1    Romualdi, E.2    Middeldorp, S.3
  • 70
    • 84859856401 scopus 로고    scopus 로고
    • Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
    • Pascale S., Petrucci G., Dragani A., et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood: 2012; 119 15 3595 3603
    • (2012) Blood , vol.119 , Issue.15 , pp. 3595-3603
    • Pascale, S.1    Petrucci, G.2    Dragani, A.3
  • 71
    • 0019378211 scopus 로고
    • Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy
    • Berk P. D., Goldberg J. D., Silverstein M. N., et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med: 1981; 304 8 441 447
    • (1981) N Engl J Med , vol.304 , Issue.8 , pp. 441-447
    • Berk, P.D.1    Goldberg, J.D.2    Silverstein, M.N.3
  • 72
    • 0022703490 scopus 로고
    • Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols
    • Berk P. D., Goldberg J. D., Donovan P. B., Fruchtman S. M., Berlin N. I., Wasserman L. R. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol: 1986; 23 2 132 143
    • (1986) Semin Hematol , vol.23 , Issue.2 , pp. 132-143
    • Berk, P.D.1    Goldberg, J.D.2    Donovan, P.B.3    Fruchtman, S.M.4    Berlin, N.I.5    Wasserman, L.R.6
  • 73
    • 33845900474 scopus 로고    scopus 로고
    • The haematocrit and platelet target in polycythemia vera
    • European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators
    • Di Nisio M., Barbui T., Di Gennaro L., et al. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators The haematocrit and platelet target in polycythemia vera. Br J Haematol: 2007; 136 2 249 259
    • (2007) Br J Haematol , vol.136 , Issue.2 , pp. 249-259
    • Di Nisio, M.1    Barbui, T.2    Di Gennaro, L.3
  • 74
    • 84859633059 scopus 로고    scopus 로고
    • The CYTO-PV: A large-scale trial testing the intensity of cytoreductive therapy to prevent cardiovascular events in patients with polycythemia vera
    • Marchioli R., Finazzi G., Specchia G., Masciulli A., Mennitto M. R., Barbui T. The CYTO-PV: A large-scale trial testing the intensity of cytoreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis: 2011; 2011 794240
    • (2011) Thrombosis , vol.2011 , pp. 794240
    • Marchioli, R.1    Finazzi, G.2    Specchia, G.3    Masciulli, A.4    Mennitto, M.R.5    Barbui, T.6
  • 75
    • 0028913012 scopus 로고
    • Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
    • Cortelazzo S., Finazzi G., Ruggeri M., et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med: 1995; 332 17 1132 1136
    • (1995) N Engl J Med , vol.332 , Issue.17 , pp. 1132-1136
    • Cortelazzo, S.1    Finazzi, G.2    Ruggeri, M.3
  • 76
    • 79959203501 scopus 로고    scopus 로고
    • Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms
    • Björkholm M., Derolf A. R., Hultcrantz M., et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol: 2011; 29 17 2410 2415
    • (2011) J Clin Oncol , vol.29 , Issue.17 , pp. 2410-2415
    • Björkholm, M.1    Derolf, A.R.2    Hultcrantz, M.3
  • 77
    • 8344229870 scopus 로고    scopus 로고
    • Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
    • Passamonti F., Rumi E., Pungolino E., et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med: 2004; 117 10 755 761
    • (2004) Am J Med , vol.117 , Issue.10 , pp. 755-761
    • Passamonti, F.1    Rumi, E.2    Pungolino, E.3
  • 78
    • 56249104095 scopus 로고    scopus 로고
    • Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms
    • Kiladjian J. J., Chomienne C., Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia: 2008; 22 11 1990 1998
    • (2008) Leukemia , vol.22 , Issue.11 , pp. 1990-1998
    • Kiladjian, J.J.1    Chomienne, C.2    Fenaux, P.3
  • 79
    • 33746307253 scopus 로고    scopus 로고
    • Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha
    • Silver R. T. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer: 2006; 107 3 451 458
    • (2006) Cancer , vol.107 , Issue.3 , pp. 451-458
    • Silver, R.T.1
  • 80
    • 73949090770 scopus 로고    scopus 로고
    • Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
    • Quintás-Cardama A., Kantarjian H., Manshouri T., et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol: 2009; 27 32 5418 5424
    • (2009) J Clin Oncol , vol.27 , Issue.32 , pp. 5418-5424
    • Quintás-Cardama, A.1    Kantarjian, H.2    Manshouri, T.3
  • 81
    • 54049141336 scopus 로고    scopus 로고
    • Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
    • Kiladjian J. J., Cassinat B., Chevret S., et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood: 2008; 112 8 3065 3072
    • (2008) Blood , vol.112 , Issue.8 , pp. 3065-3072
    • Kiladjian, J.J.1    Cassinat, B.2    Chevret, S.3
  • 82
    • 0037217859 scopus 로고    scopus 로고
    • Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia
    • Alvarado Y., Cortes J., Verstovsek S., et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol: 2003; 51 1 81 86
    • (2003) Cancer Chemother Pharmacol , vol.51 , Issue.1 , pp. 81-86
    • Alvarado, Y.1    Cortes, J.2    Verstovsek, S.3
  • 83
    • 27144539129 scopus 로고    scopus 로고
    • Pegylated interferon for the treatment of high risk essential thrombocythemia: Results of a phase II study
    • Langer C., Lengfelder E., Thiele J., et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica: 2005; 90 10 1333 1338
    • (2005) Haematologica , vol.90 , Issue.10 , pp. 1333-1338
    • Langer, C.1    Lengfelder, E.2    Thiele, J.3
  • 84
    • 33646470836 scopus 로고    scopus 로고
    • A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: Feasibility, clinical and biologic effects, and impact on quality of life
    • Nordic Study Group for Myeloproliferative Disorders
    • Samuelsson J., Hasselbalch H., Bruserud O., et al. Nordic Study Group for Myeloproliferative Disorders A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer: 2006; 106 11 2397 2405
    • (2006) Cancer , vol.106 , Issue.11 , pp. 2397-2405
    • Samuelsson, J.1    Hasselbalch, H.2    Bruserud, O.3
  • 85
    • 84863393110 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
    • Verstovsek S., Mesa R. A., Gotlib J., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med: 2012; 366 9 799 807
    • (2012) N Engl J Med , vol.366 , Issue.9 , pp. 799-807
    • Verstovsek, S.1    Mesa, R.A.2    Gotlib, J.3
  • 86
    • 77956696835 scopus 로고    scopus 로고
    • Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
    • Verstovsek S., Kantarjian H., Mesa R. A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med: 2010; 363 12 1117 1127
    • (2010) N Engl J Med , vol.363 , Issue.12 , pp. 1117-1127
    • Verstovsek, S.1    Kantarjian, H.2    Mesa, R.A.3
  • 87
    • 84863393110 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
    • Verstovsek S., Mesa R. A., Gotlib J., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med: 2012; 366 9 799 807
    • (2012) N Engl J Med , vol.366 , Issue.9 , pp. 799-807
    • Verstovsek, S.1    Mesa, R.A.2    Gotlib, J.3
  • 88
    • 84857837774 scopus 로고    scopus 로고
    • JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
    • Harrison C., Kiladjian J. J., Al-Ali H. K., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med: 2012; 366 9 787 798
    • (2012) N Engl J Med , vol.366 , Issue.9 , pp. 787-798
    • Harrison, C.1    Kiladjian, J.J.2    Al-Ali, H.K.3
  • 89
    • 79952333359 scopus 로고    scopus 로고
    • Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
    • Pardanani A., Gotlib J. R., Jamieson C., et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol: 2011; 29 7 789 796
    • (2011) J Clin Oncol , vol.29 , Issue.7 , pp. 789-796
    • Pardanani, A.1    Gotlib, J.R.2    Jamieson, C.3
  • 91
    • 0037775584 scopus 로고    scopus 로고
    • Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
    • Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators
    • Lee A. Y., Levine M. N., Baker R. I., et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med: 2003; 349 2 146 153
    • (2003) N Engl J Med , vol.349 , Issue.2 , pp. 146-153
    • Lee, A.Y.1    Levine, M.N.2    Baker, R.I.3
  • 92
    • 42949153260 scopus 로고    scopus 로고
    • Heparin-induced thrombocytopenia in myeloproliferative disorders: A rare or under-diagnosed complication
    • Spectre G., Kalish Y., Schliamser L., Varon D. Heparin-induced thrombocytopenia in myeloproliferative disorders: a rare or under-diagnosed complication? Am J Hematol: 2008; 83 5 420 423
    • (2008) Am J Hematol , vol.83 , Issue.5 , pp. 420-423
    • Spectre, G.1    Kalish, Y.2    Schliamser, L.3    Varon, D.4
  • 93
    • 75649116507 scopus 로고    scopus 로고
    • Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis
    • Randi M. L., Tezza F., Scapin M., et al. Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis. Acta Haematol: 2010; 123 3 140 145
    • (2010) Acta Haematol , vol.123 , Issue.3 , pp. 140-145
    • Randi, M.L.1    Tezza, F.2    Scapin, M.3
  • 94
    • 0025048792 scopus 로고
    • A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders
    • Wehmeier A., Fricke S., Scharf R. E., Schneider W. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. Eur J Haematol: 1990; 45 4 191 197
    • (1990) Eur J Haematol , vol.45 , Issue.4 , pp. 191-197
    • Wehmeier, A.1    Fricke, S.2    Scharf, R.E.3    Schneider, W.4
  • 95
    • 0018163875 scopus 로고
    • Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors
    • Kaywin P., McDonough M., Insel P. A., Shattil S. J. Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors. N Engl J Med: 1978; 299 10 505 509
    • (1978) N Engl J Med , vol.299 , Issue.10 , pp. 505-509
    • Kaywin, P.1    McDonough, M.2    Insel, P.A.3    Shattil, S.J.4
  • 96
    • 0024403073 scopus 로고
    • Platelet membrane abnormalities in myeloproliferative disorders: Decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function
    • Mazzucato M., De Marco L., De Angelis V., De Roia D., Bizzaro N., Casonato A. Platelet membrane abnormalities in myeloproliferative disorders: decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function. Br J Haematol: 1989; 73 3 369 374
    • (1989) Br J Haematol , vol.73 , Issue.3 , pp. 369-374
    • Mazzucato, M.1    De Marco, L.2    De Angelis, V.3    De Roia, D.4    Bizzaro, N.5    Casonato, A.6
  • 97
    • 0032530687 scopus 로고    scopus 로고
    • Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera
    • Le Blanc K., Lindahl T., Rosendahl K., Samuelsson J. Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. Thromb Res: 1998; 91 6 287 295
    • (1998) Thromb Res , vol.91 , Issue.6 , pp. 287-295
    • Le Blanc, K.1    Lindahl, T.2    Rosendahl, K.3    Samuelsson, J.4
  • 98
    • 0029951483 scopus 로고    scopus 로고
    • The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count
    • van Genderen P. J., Budde U., Michiels J. J., van Strik R., van Vliet H. H. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol: 1996; 93 4 962 965
    • (1996) Br J Haematol , vol.93 , Issue.4 , pp. 962-965
    • Van Genderen, P.J.1    Budde, U.2    Michiels, J.J.3    Van Strik, R.4    Van Vliet, H.H.5
  • 99
    • 0031472388 scopus 로고    scopus 로고
    • Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: Normalization after cytoreduction of the increased platelet count
    • van Genderen P. J., Prins F. J., Lucas I. S., et al. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. Br J Haematol: 1997; 99 4 832 836
    • (1997) Br J Haematol , vol.99 , Issue.4 , pp. 832-836
    • Van Genderen, P.J.1    Prins, F.J.2    Lucas, I.S.3
  • 100
    • 0022349805 scopus 로고
    • The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: An analysis of 129 cases
    • Buss D. H., Stuart J. J., Lipscomb G. E. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am J Hematol: 1985; 20 4 365 372
    • (1985) Am J Hematol , vol.20 , Issue.4 , pp. 365-372
    • Buss, D.H.1    Stuart, J.J.2    Lipscomb, G.E.3
  • 101
    • 84859650006 scopus 로고    scopus 로고
    • Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
    • Finazzi G., Carobbio A., Thiele J., et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia: 2012; 26 4 716 719
    • (2012) Leukemia , vol.26 , Issue.4 , pp. 716-719
    • Finazzi, G.1    Carobbio, A.2    Thiele, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.